Kornimate/medical-research-clean huggingface dataset:
effectiveness monitoring of home non-invasive mechanical ventilation by digital diagnosis platform

Conditions: Neuromuscular Diseases; Obesity Hypoventilation Syndrome; Lung Disease, Restrictive

Summary: the main objective will be to determine the effectiveness of home non-invasive ventilation by flow-time and time-pressure curves analysis in a cohort of patients with this treatment by digital diagnosis platform.

a multicenter study with observational prospective design will be implemented on 3 spanish hospitals in barcelona. inclusion criteria will be equivalent sample size of patients with restrictive lung disease, neuromuscular pathology and hypoventilation-obesity. digital diagnosis platform will be used to incorporate and unify signals of different medical devices: a pneumotachograph on branch ventilator that captures pressure and flow-time signals, inductance plethysmography used to like a patient effort sensor and portable pulse oximeter recordings. nocturnal polygraphic or polysomnographic tracings performed and recorded on sites will be processed systematically by main asynchronies diagnosis algorithms between patient and ventilator. these algorithms providing global and fractionated asynchronies count based on time, leaks or saturation criteria which will be used to compared effective ventilation phases and phases with nocturnal desaturations. therefore, prevalence and asynchronies model on home niv can be determine establishing the correlation between desaturation phases and respiratory events and identifying minimum tolerable leak level to keep adequate ventilation.

Eligibility criteria:
inclusion criteria: * home non-invasive mechanical ventilation and clinical stability at least of 6 months ( no acute episode with admission on 2 months before) * mean ventilator compliance \> 4 h/ per night on screening visit * signed informed consent form previously exclusion criteria: * ventilation with oxygen join system.

Keywords: home monitoring non-invasive mechanical ventilation
efficacy of the yoga and aromatherapy on salivary hormone and immune function in pregnant women.

Conditions: Stress, Psychologic

Summary: this study's aims are to examine the effects of yoga and aromatherapy on women's stress and immune function during pregnancy.

this longitudinal, prospective, randomized controlled trial recruited 75 healthy pregnant women from a prenatal clinic in taipei using convenience sampling. the participants were randomly assigned to the aromatherapy group (n=25), yoga group (n=25) or control (n=25) group using clinstat block randomization. the aromatherapy group received 70 minutes of aromatherapy massage once biweekly for 20 weeks; the yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks; the control group received only routine prenatal care. all participants' salivary cortisol and immunoglobulin a levels were collected before and after yoga or aromatherapy every 4 weeks from 16 to 36 weeks' gestation. to collect a sufficient quantity of saliva, we used salivette® cotton swabs (salimetrics, state college, pa, usa), which were stored in double-layer plastic tubes with a lid. when participants chew a swab for about 2 to 3 minutes, saliva flow is stimulated to a sufficient amount (1 ml) for collection. after the tube was centrifuged at 1000 x g for 2 minutes, saliva was stored at -80°c until assay for salivary cortisol and iga concentrations. cortisol was measured using a competitive enzyme-linked immunoassay (elisa) kit (cayman chemical company, usa), and salivary iga was measured using double-antibody sandwich elisa method per the manufacturer's instruction (icl, inc., usa).

Eligibility criteria:
inclusion criteria: * normal pregnancy * age 20-45 years * agreed to follow-up collections of saliva samples * could read and write chinese exclusion criteria: * oral steroid use * history of severe illness (e.g., heart disease, systemic lupus erythaematosus, metabolic disorders) or depression. * drug use (prescribed or illicit). * high-risk pregnancy (i.e., first-trimester vaginal bleeding, artificially insemination, multiple gestations, foetal growth restriction or other abnormalities).

Keywords: aromatherapy massage, yoga
effect of udca on the new onset diabetes and glucose intolerance induced by statin

Conditions: Diabetes Mellitus

Summary: at present, it is recognized that statins are the cornerstone of treatment for the prevention of major cardiovascular events in patients with atherosclerotic cardiovascular disease (ascvd); however, at the same time, the increased risk of long-term glucose tolerance and type 2 diabetes mellitus caused by statin therapy has attracted wide attention. the investigators' recent study found that the levels of glycosylated hemoglobin, insulin and c-peptide increased significantly with the extension of follow-up time in patients with hyperlipidemia. at the same time, serum and fecal bile acid metabolism profiles, especially secondary bile acid metabolism, were extensively changed, especially in ursodeoxycholic acid (udca), suggesting that the decrease of udca is a possible mechanism for statins to induce side effects of diabetes. according to this hypothesis, ursodeoxycholic acid combined with statins may improve the abnormal glucose tolerance caused by statins and maximize the benefit of statins. this study is a multicenter, prospective, randomized, parallel, double-blind placebo-controlled, cohort study. taking ascvd patients as the research object, the investigators will compare the changes of glycosylated hemoglobin, fasting blood glucose, fasting insulin, c-peptide and metabolomic indexes before and after the use of ursodeoxycholic acid combined with atorvastatin and atorvastatin alone and during follow-up, further evaluate the changes of blood glucose related indexes before and after the use of ursodeoxycholic acid combined with atorvastatin and atorvastatin alone, clarify the possible mechanism and specific treatment targets of abnormal glucose tolerance caused by statin, and put forward a possible alternative treatment for the disorder of glucose metabolism caused by statin.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old and \< 80 years old, regardless of gender; * for those who had indications for taking statins for more than half a year, glycosylated hemoglobin increased by more than 0.5 and \> 6.1% compared with half a year ago; * agree to accept the study treatment plan and voluntarily sign the informed consent form. exclusion criteria: * previous diagnosis of diabetes mellitus; * received hypoglycemic drug treatment; * the level of abdominal blood glucose at baseline was ≥ 7mmol / l; * need to take glucocorticoids for a long time; * acute myocardial infarction and stroke occurred in the last 6 months; * severe liver dysfunction; * glomerular filtration rate (egfr) \< 30ml / min / 1.73m2 (mdrd formula); * malignant tumor; * blood system diseases; * acute or severe systemic infection; * women during pregnancy, lactation and preparation for pregnancy; * alcohol and other drug addicts and mental patients; * patients who are participating in other clinical studies or withdraw from less than 1 month;
efficacy of two prophylactic schedules (prulifloxacin versus phosphomycin)

Conditions: Urinary Tract Infection

Summary: epidemiological studies showed that 20-30% of patients with uncomplicated urinary tract infections risked recurrent infection. urinary tract infection causes marked discomfort for the patient, has a negative impact upon quality of life, and is associated with high social and health costs in terms of specialist appointments, laboratory and instrumental tests and prescriptions . although diverse cycles of antibiotic therapy and prophylaxis have been proposed, doubts persist about the most efficacious pharmacological agents, duration of prophylaxis , the incidence of adverse effects and relapse when antibiotic therapy is suspended. aims of the study: 1. to compare the efficacy of two prophylactic schedules (prulifloxacin vs phosphomycin): * in reducing the number of urinary tract infection episodes during prophylaxis * in reducing the number of urinary tract infection episodes after prophylaxis * in improving the patient's quality of life . 2. to assess : * tolerability of antibiotic prophylaxis * the incidence of resistance to antibiotic therapy


Eligibility criteria:
inclusion criteria: * female patients * age over 18 years old * no allergies to the drugs to be prescribed * no counter-indications to this drug therapy * urine culture shows responsiveness to drugs at recruitment of patient * history of urinary tract infections with at least three episodes in the previous year or two in the past six months exclusion criteria: * lack of tolerability of prescribed drugs

Keywords: prophylasy recurrent urinary tract infection prulifloxacin phosphomycin
effect of addition of short course of prednisolone to gluten free diet in naive celiac disease patients

Conditions: Celiac Disease

Summary: withdrawal of gluten, the culprit antigen, is the definite treatment for celiac disease. weeks to months after gluten withdrawal from the diet before the clinical manifestations, histological features start improving. many of the adult patients are in the critical phase where even weeks may matter especially those in their adolescence where height growth has limited potential. suppression of immune system using a short course of steroid might retard the immune mediated destruction of the villi while the effect of gluten withdrawal sets in. steroids are known to be effective in the management of refractory celiac disease. therefore, the investigators hypothesized that addition of a short course of steroid to gluten free diet may enhance intestinal mucosal recovery and thus clinical manifestations

celiac disease is a chronic systemic autoimmune disorder induced by gluten proteins present in wheat, barley, and rye. steroids affect proliferative responses of both b and t cells in vitro, and the production of lymphokines (migratory inhibitory factor) by cultured cells. steroids inhibit the effect of gluten proteins through their action on elements of the immune system. glucocorticoids are reserved for severely ill patients, who present with celiac crisis, gliadin shock, and refractory sprue. we hypothesized that addition of a short course of steroid to gluten free diet may enhance intestinal mucosal recovery and thus clinical manifestations.

Eligibility criteria:
inclusion criteria: * naïve patients with celiac disease (cd will be diagnosed as per revised european society of pediatric gastroenterology and nutrition criteria * both sexes * age\>12 years exclusion criteria: * partially treated celiac disease * co-existent systemic diseases * hiv seropositive * seropositive with hbsag , anti hcv ab * past h/o tuberculosis * evidence of active tuberculosis * unwilling patient

Keywords: celiac disease, steroids, immunohistochemistry
families with pride ("familias con orgullo").

Conditions: Depression; Drug Use

Summary: this study will evaluate the effects of a parenting intervention for hispanic sexual minority youth in preventing/reducing drug use and depressive symptoms. it will also examine whether the intervention improves parent social support for the adolescent, parent acceptance, family functioning, and whether it reduces general stress and stress associated with being a hispanic sexual minority.


Eligibility criteria:
inclusion criteria: * youth, 13 - 19, who report at least one of the following: a) identify as gay, lesbian, or bisexual, or b) reports same-sex sexual behavior. * adolescent has their disclosed their sexual minority status to at least one parent. * adolescent is of hispanic immigrant origin, defined by having at least one parent that self-identifies as hispanic (english and spanish speaking hispanics can participate in the study). * adolescent lives with an adult parent who is willing to participate. * family lives in south florida exclusion criteria: * adolescent identifies as transgender. * family plans to move out of south florida during the study period

Keywords: randomized controlled trial hispanic sexual minority youth parent-centered
effectiveness of hyaluronic acid gel in the prevention of intrauterine adhesions after second trimester abortion

Conditions: Placenta Retained; Uterine Diseases

Summary: this prospective, randomized, controlled study evaluates the efficacy of self-crosslinked hyaluronic acid gel to prevent the development of de-novo intrauterine adhesions following curettage for retained product after second trimester abortion. one group of participants will underwent curettage plus intrauterine application of self-crosslinked hyaluronic acid gel while the other group will underwent curettage alone (control group).

intrauterine adhesions are the major long-term complication of curettage for retained products of conception. the risk of adhesion is higher after second trimester abortion. this complication may result in infertility, recurrent miscarriages and irregular periods with dysmenorrhea and pelvic pain. they have been reported that the intrauterine application of auto-crosslinked hyaluronic acid gel following hysteroscopic adhesiolysis or hysteroscopic surgery significantly reduces the formation of post-operative intrauterine adhesions. the aim of this prospective, randomized, controlled study is to evaluate the efficacy of self-crosslinked hyaluronic acid gel in the reduction of development of de-novo post-curettage adhesions at 2 months follow-up.

Eligibility criteria:
inclusion criteria: * subject has curettage for retained product after second trimester abortion exclusion criteria: * history of curettage or other intrauterine surgery * history of post-abortion complication or infection
ct-2106 for the second line treatment of ovarian cancer

Conditions: Ovarian Cancer

Summary: the purpose of this sudy is to determine the response rate of ct-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.


Eligibility criteria:
inclusion criteria: * patients with advanced ovarian carcinoma, who have failed one prior platinum and taxane containing regimen * only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes administered concomitantly * at least one measurable lesion according to recist * ecog performance status 0 or 1 * at least 18 years old * adequate haematological function * adequate renal and hepatic functions * normal coagulation parameters exclusion criteria: * platinum-sensitive patients (group 2) who responded (cr or pr) to a 1st line therapy and subsequently progressed or relapsed after a treatment-free interval of \> 12 months * pregnant or lactating patients * prior treatment with camptothecins * presence or history of cns metastasis or carcinomatous leptomeningitis; * current active infection per investigator assessment; * unresolved bowel obstruction or subobstruction, uncontrolled crohn's disease or ulcerative colitis; * current history of chronic diarrhea \>= grade 1 (ctcae version 3); * surgery or radiotherapy ≤ 4 weeks before first study treatment. in case of cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st study treatment are allowed; * other uncontrolled, serious illness or medical condition, as determined by the investigator; * concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation; * concurrent treatment with any other anti-cancer therapy; * known hiv positivity or aids-related illness; * patients who cannot be regularly followed up for psychological, social, familial or geographic reasons.

Keywords: ovarian ct-2106
safety and efficacy of bronchitol in bronchiectasis

Conditions: Bronchiectasis

Summary: study will assess the safety and effectiveness of 12 week treatment with the study medication, bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). past studies have shown bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. on completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.


Eligibility criteria:
inclusion criteria: * non cystic fibrosis bronchiectasis * have fev1 50% - 80% predicted and ≥1.0l * have chronic sputum production of \>10 ml per day on the majority of days in the 3 months prior to study entry exclusion criteria: * be using hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry * have airway hyperresponsiveness as defined by a positive aridol challenge

Keywords: mannitol
neutrophil-to-lymphocyte ratio in bladder cancer: a secondary biomarker analysis of swog 8710

Conditions: Bladder Cancer

Summary: the purpose of this study is to perform a secondary analysis of swog 8710 to assess nlrs value as a biomarker. specifically, the investigators test two hypotheses: 1) that baseline nlr is correlated with overall survival after curative treatment for bc and 2) that baseline nlr is correlated with the survival benefit of nac. the study will look at the data from participants of the swog 8710 study.


Eligibility criteria:
inclusion criteria: 1. swog 8710 original trial inclusion criteria included: * node-negative, muscle-invasive transitional cell carcinoma of the bladder, t2-t4an0m0 per the ajcc 4th edition staging manual. * swog performance status of 0 or 1 * adequate organ function by lab criteria (wbc \> 4,000 cells/mm3, platelets \>150,000 cells/mm3, creatinine \<1.5 md/dl (men) or \<1.3 md/dl (women), baseline liver tests \< 2 times normal limits) 2. inclusion criteria for this secondary analysis are: * eligible for original swog 8710 trial * had complete blood count with differential prior to first treatment (radical cystectomy or nac). exclusion criteria: 1. swog 8710 original trial exclusion criteria included: * no age restrictions * previous or concomitant malignancy other than bladder cancer or basal cell skin cancer * prior pelvic radiation * metastatic or incurable disease * laboratory values exceeding those detailed in 3.1.c 2. exclusion criteria for this secondary analysis are: * ineligibility for the original swog 8710 study * lack of complete blood count with differential prior to first treatment (cystectomy or nac).
efficacy and safety of immunotherapy in non-small cell lung cancer with uncommon histological type

Conditions: Uncommon Pathological Types of Lung Cancer

Summary: this study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world. through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.the patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.

this is a research project involving patients in medical oncology department of affiliated cancer hospital of xiangya school of medicine central south university. retrospective study of 40 patients with advanced uncommon pathological types of lung cancer and observe the efficacy and safety of immune checkpoint inhibitor regimen in the real world. the patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two. statistical analysis is used to compare the differences between the two treatments, so that patients can better choose treatment strategies.

Eligibility criteria:
inclusion criteria: * 18，advanced uncommon pathological types of lung cancer by histopathology whether or not it is accompanied by a driver mutation treatment plan is pembrolizumab 200mg iv q21d exclusion criteria: - patients received antitumor treatment before patients with contraindication of chemotherapy pregnant or breast feeding women

Keywords: uncommon pathological types of lung cancer immune checkpoint inhibitor
low dose ketamine vr analgesia during burn care procedure

Conditions: Burn

Summary: the purpose of the research is to see whether a low dose of ketamine, a medication used to reduce pain, enhances the effectiveness of a virtual reality video game, which is used as a form of distraction from pain during a painful burn care procedure.

this study is conducted in a hospital setting. it is a randomized controlled trial comparing the use of virtual reality distraction (vrd) and standard pain medications to the use of vrd, standard pain medications and a single low dose of ketamine as a means to reduce pain during a painful procedure in patients in the hospital.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * compliant and able to complete questionnaires * no history of psychiatric disorder * not demonstrating delirium, psychosis or any form of organic brain disorder * able to communicate verbally * english-speaking * iv access already in place exclusion criteria: * age less than 18 years * not capable of indicating pain intensity * not capable of filling out study measures * evidence of traumatic brain injury * history of psychiatric disorder * demonstrating delirium, psychosis or any form of organic brain disorder and associated memory problems * unable to communicate orally * receiving prophylaxis for alcohol or drug withdrawal * developmental disability * any face/head/neck injuries that interfere with the use of virtual reality equipment * non-english speaking * extreme susceptibility to motion sickness * seizure history * no iv access already in place

Keywords: virtual reality ketamine